BACKGROUND: Minority populations in the United States, especially blacks and Hispanics, are generally underrepresented among participants in clinical trials. Here, we report the experience of enrolling ethnic minorities in a large cancer screening trial. METHODS: The Prostate, Colorectal, Lung and Ovarian (PLCO) Cancer Screening Trial is a multicenter randomized trial designed to evaluate the effectiveness of screening for the PLCO cancers. Subjects were recruited at 10 U.S. centers between 1993 and 2001. One screening center had a major special recruitment effort for blacks and another center had a major special recruitment effort for Hispanics. RESULTS: Among almost 155,000 subjects enrolled in PLCO, minority enrollment was as follows: black (5.0%), Hispanic (1.8%) and Asian (3.6%). This compares to an age-eligible population in the combined catchment areas of the PLCO centers that was 14.0% black, 2.9% Hispanic and 5.4% Asian, and an age-eligible population across the U.S. that was 9.5% black, 6.5% Hispanic and 3.0% Asian. About half (45%) of Hispanics were recruited at the center with the special Hispanic recruitment effort. Seventy percent of blacks were recruited at two centers; the one with the major special recruitment effort and a center in Detroit whose catchment area was 20% black among age-eligibles. Blacks, Hispanics and (non-Hispanic) whites were all more highly educated, less likely to currently smoke and more likely to get regular exercise than their counterparts in the general population. CONCLUSION: Significant efforts were made to recruit racial/ ethnic minorities into PLCO, and these efforts resulted in enrollment levels that were comparable to those seen in many recent cancer screening or prevention trials. Blacks and Hispanics were nonetheless underrepresented in PLCO compared to their levels among age-eligibles in the overall U.S. population or in the aggregate PLCO catchment areas.
RCT Entities:
BACKGROUND: Minority populations in the United States, especially blacks and Hispanics, are generally underrepresented among participants in clinical trials. Here, we report the experience of enrolling ethnic minorities in a large cancer screening trial. METHODS: The Prostate, Colorectal, Lung and Ovarian (PLCO) Cancer Screening Trial is a multicenter randomized trial designed to evaluate the effectiveness of screening for the PLCO cancers. Subjects were recruited at 10 U.S. centers between 1993 and 2001. One screening center had a major special recruitment effort for blacks and another center had a major special recruitment effort for Hispanics. RESULTS: Among almost 155,000 subjects enrolled in PLCO, minority enrollment was as follows: black (5.0%), Hispanic (1.8%) and Asian (3.6%). This compares to an age-eligible population in the combined catchment areas of the PLCO centers that was 14.0% black, 2.9% Hispanic and 5.4% Asian, and an age-eligible population across the U.S. that was 9.5% black, 6.5% Hispanic and 3.0% Asian. About half (45%) of Hispanics were recruited at the center with the special Hispanic recruitment effort. Seventy percent of blacks were recruited at two centers; the one with the major special recruitment effort and a center in Detroit whose catchment area was 20% black among age-eligibles. Blacks, Hispanics and (non-Hispanic) whites were all more highly educated, less likely to currently smoke and more likely to get regular exercise than their counterparts in the general population. CONCLUSION: Significant efforts were made to recruit racial/ ethnic minorities into PLCO, and these efforts resulted in enrollment levels that were comparable to those seen in many recent cancer screening or prevention trials. Blacks and Hispanics were nonetheless underrepresented in PLCO compared to their levels among age-eligibles in the overall U.S. population or in the aggregate PLCO catchment areas.
Authors: Irina Mordukhovich; Paul L Reiter; Danielle M Backes; Leila Family; Lauren E McCullough; Katie M O'Brien; Hilda Razzaghi; Andrew F Olshan Journal: Cancer Causes Control Date: 2010-12-24 Impact factor: 2.506
Authors: Adeyinka O Laiyemo; Chyke Doubeni; Paul F Pinsky; V Paul Doria-Rose; Robert Bresalier; Lois E Lamerato; E David Crawford; Paul Kvale; Mona Fouad; Thomas Hickey; Thomas Riley; Joel Weissfeld; Robert E Schoen; Pamela M Marcus; Philip C Prorok; Christine D Berg Journal: J Natl Cancer Inst Date: 2010-03-31 Impact factor: 13.506
Authors: Omotola S Ashorobi; Jacqueline Frost; Xuemei Wang; Pamela Roberson; E Lin; Robert J Volk; David S Lopez; Lovell A Jones; Curtis A Pettaway Journal: Am J Mens Health Date: 2016-07-08
Authors: Melissa A Green; Margo Michaels; Natasha Blakeney; Adebowale A Odulana; Malika Roman Isler; Alan Richmond; Debra G Long; William S Robinson; Yhenneko J Taylor; Giselle Corbie-Smith Journal: J Cancer Educ Date: 2015-03 Impact factor: 2.037
Authors: Samantha A Barry; Martin C Tammemagi; Sofiya Penek; Elisabeth C Kassan; Caroline S Dorfman; Thomas L Riley; John Commin; Kathryn L Taylor Journal: J Natl Cancer Inst Date: 2012-10-26 Impact factor: 13.506
Authors: Margaret G Stineman; Neville Strumpf; Jibby E Kurichi; Jeremy Charles; Jeane Ann Grisso; Ravishankar Jayadevappa Journal: Gerontologist Date: 2011-06
Authors: Marvella E Ford; Laura A Siminoff; Elisabeth Pickelsimer; Arch G Mainous; Daniel W Smith; Vanessa A Diaz; Lea H Soderstrom; Melanie S Jefferson; Barbara C Tilley Journal: Health Soc Work Date: 2013-02
Authors: Adebowale Odulana; Mimi M Kim; Melissa Green; Yhenneko Taylor; Daniel L Howard; Paul Godley; Giselle Corbie-Smith Journal: J Relig Health Date: 2014-04